Malignant Reproductive System Neoplasm — Trials

Malignant Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,804
Recruiting: 1,546
Ph III recruiting: 175
Growth YoY: +16.2%
Industry share: 21%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,473)

clinicaltrialsPublishedShowing 301–350 of 5,271 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04814108	A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma	completed	Phase 2	92	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY	4	Mar 18, 2026	clinicaltrials
NCT05198804	A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	completed	Phase 1 / Phase 2	117	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY